Paradis V, Ferlicot S, Ghannam E, Zeimoura L, Blanchet P, Eschwége P, Jardin A, Benoît G, Bedossa P
Department of Pathology, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
J Urol. 1999 Jun;161(6):1984-7.
CD44 is a transmembrane glycoprotein involved in cell-cell and cell-matrix interactions. De novo expression of CD44 and its variant isoforms has been associated with aggressive behavior in various tumors. Since few data are available concerning the role of CD44 in the biological behavior of locally confined renal tumors, we analyzed the expression of CD44 in a large set of conventional renal cell carcinomas to determine its prognostic value in association with other clinicopathologic variables.
Ninety-one patients with locally confined conventional renal cell carcinomas were studied. CD44 standard form (CD44H) and v6 isoform expressions were semiquantitatively evaluated on paraffin-embedded tumor tissue by immunohistochemistry. The prognostic value of the usual clinicopathological variables and CD44 expression was tested using Kaplan-Meier plots by the log rank test and Cox multiple hazard regression analysis.
No immunostaining was observed in normal renal tissue. Thirty-two of the 66 conventional renal cell carcinomas (48%) showed CD44H membranous staining of the tumor cells. Only 2 cancers displayed CD44v6 immunostaining. Among the different clinicopathological variables analyzed, tumor stage (p = 0.001), nuclear grade (p = 0.01), size (p = 0.02), vascular (p = 0.05) and perirenal adipose tissue invasion (p = 0.005), and CD44H expression (p = 0.01) were found to be significant prognostic parameters for survival using univariate analysis. Moreover, multivariate analysis indicated stage, nuclear grade and CD44 expression as independent prognostic factors both for overall and disease-free survival.
CD44 can be considered as a useful prognostic parameter in conventional renal cell carcinoma and may be used in evaluation of the outcome of these tumors.
CD44是一种参与细胞间和细胞与基质相互作用的跨膜糖蛋白。CD44及其变异体的从头表达与多种肿瘤的侵袭性行为相关。由于关于CD44在局限性肾肿瘤生物学行为中的作用的数据较少,我们分析了大量传统肾细胞癌中CD44的表达,以确定其与其他临床病理变量相关的预后价值。
研究了91例局限性传统肾细胞癌患者。通过免疫组织化学对石蜡包埋的肿瘤组织进行半定量评估CD44标准型(CD44H)和v6变异体的表达。使用Kaplan-Meier曲线通过对数秩检验和Cox多因素风险回归分析来检验常见临床病理变量和CD44表达的预后价值。
在正常肾组织中未观察到免疫染色。66例传统肾细胞癌中有32例(48%)显示肿瘤细胞有CD44H膜染色。仅2例癌症显示CD44v6免疫染色。在分析的不同临床病理变量中,单因素分析发现肿瘤分期(p = 0.001)、核分级(p = 0.01)、大小(p = 0.02)、血管(p = 0.05)和肾周脂肪组织浸润(p = 0.005)以及CD44H表达(p = 0.01)是生存的重要预后参数。此外,多因素分析表明分期、核分级和CD44表达是总生存和无病生存的独立预后因素。
CD44可被视为传统肾细胞癌中一个有用的预后参数,并可用于评估这些肿瘤的预后。